DEP always first, page-7

Originally posted by col69
I do find it a bit weird that we have not been designated a meeting date with the FDA given we are at the 8th March 2019 and the Shareholder Update announcement on the 17th January said this:

The meeting, which is expected to be scheduled during the next six-to-eight weeks,

While I can appreciate that this was only a guide and the fact that SPL may not even advise the market of this meeting date, the longer it takes to get organised the longer the new trials are away from starting ? ​

Perhaps they meant that they would schedule a time in the next 6-8 weeks to discuss setting a time to have a meeting about when they would be able to schedule a time to meet to discuss what a complete response letter is and then go from there.